offline
Regeneron's (REGN) Q1 Earnings & Sales Surpass Estimates
Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected results for the first quarter of 2020, wherein both earnings and sales beat estimates.
Shares are up in pre-market trading on strong results. Shares of Regeneron have gained 44.3% in the year so far compared with the industry’s growth of 1.7%.
...
The company reported earnings of $6.60 per share in the first quarter, comfortably beating the Zacks Consensus Estimate of $5.73 and increasing from $4.45 in the year-ago quarter.
Total revenues in the reported quarter jumped 33% year over year to $1.8 billion and comfortably beat the Zacks Consensus Estimate of $1.7 billion. However, revenues were down sequentially from $2.2 billion. The year-over-year growth was driven by strong Eylea and Dupixent sales.
...
https://finance.yahoo.com/news/regeneron...01588.html
![[Bild: REGNc1dl0327.png]](https://finviz.com/publish/050620/REGNc1dl0327.png)
Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected results for the first quarter of 2020, wherein both earnings and sales beat estimates.
Shares are up in pre-market trading on strong results. Shares of Regeneron have gained 44.3% in the year so far compared with the industry’s growth of 1.7%.
...
The company reported earnings of $6.60 per share in the first quarter, comfortably beating the Zacks Consensus Estimate of $5.73 and increasing from $4.45 in the year-ago quarter.
Total revenues in the reported quarter jumped 33% year over year to $1.8 billion and comfortably beat the Zacks Consensus Estimate of $1.7 billion. However, revenues were down sequentially from $2.2 billion. The year-over-year growth was driven by strong Eylea and Dupixent sales.
...
https://finance.yahoo.com/news/regeneron...01588.html
__________________
